Brief: Tiziana Life Sciences Applied For FDA Orphan Drug Designation Of Foralumab For na-SPMS
06/06/2024 14:09
June 6 (Reuters) - Tiziana Life Sciences Ltd TLSA.O :
* TIZIANA LIFE SCIENCES LTD: APPLIED FOR FDA ORPHAN DRUG
DESIGNATION OF FORALUMAB FOR NA-SPMS
Source text for Eikon: ID:nGNX7Jbs3S
Further company coverage: TLSA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tiziana Life Sciences
See all newsBrief: Tiziana Announces New Positive Clinical Data For Intranasal Foralumab In Non-Active Secondary Progressive Multiple Sclerosis
U.S. STOCKS ON THE MOVE -Viatris, Clear Secure, Bicara
U.S. STOCKS ON THE MOVE-Sharps Technology, Whirlpool, Applovin
U.S. STOCKS ON THE MOVE-Oracle, Vanda, Keysight
Tiziana Life Sciences rises as nasal MS drug shows promise in early study